Biotechnology

INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China

PLYMOUTH MEETING, Pa. and SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("...

2020-12-10 21:00 5491

ReCor Medical Announces Positive Results in RADIANCE-HTN TRIO Study and Breakthrough Device Designation for Paradise™ Ultrasound Renal Denervation System

PALO ALTO, Calif., Dec. 10, 2020 /PRNewswire/ -- ReCor Medical, Inc. ("ReCor"), a wholly-owned subsidiary of Otsuka Medical Devices, announced today that its Paradise™ Ultrasound Renal Denervation System (the "Paradise System") demonstrated positive results in the RADIANCE-HTN TRIO ("TRIO") study...

2020-12-10 16:01 1442

InDevR Expands Commercial Portfolio for Coronavirus Vaccine Characterization

BOULDER, Colo., Dec. 10, 2020 /PRNewswire/ -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray® Spike Protein Kit and SARS-CoV-2 Spike ...

2020-12-10 15:00 1167

Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG

SYDNEY, Dec. 10, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a Letter of Intent with the Pacific Pediatric Neuro-Oncology Consortium (PNOC) to launch a clinical trial of...

2020-12-10 12:51 6346

PharmAbcine presents the latest data of the ongoing Phase Ib mTNBC trial at SABCS 2020

DAEJEON, South Korea, Dec. 9, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today the presentation of the latest interim data from its ongoing phase Ib combination trial of oli...

2020-12-09 23:00 1477

RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium - RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negativ...

2020-12-09 22:00 2879

Northway Biotechpharma, Biologics CDMO, Announces Company Brand Name Change to Northway Biotech

VILNIUS, Lithuania and WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Northway Biotechpharma, providing end-to-end contract drug development and manufacturing (CDMO) services, announces brand name change toNorthway Biotech. Along with the tradename change, Dr. Vladas Algirdas Bumelis also returns t...

2020-12-09 21:39 1351

INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18

PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive Phase 2 efficacy ...

2020-12-09 21:00 4123

MiCAN Technologies' myeloid lineage cells help researchers fight COVID-19

KYOTO, Japan, Dec. 9, 2020 /PRNewswire/ -- MiCAN Technologies , a research service provider based in Kyoto Japan, revealed today that its human myeloid lineage cells[1] have been used to conduct research on the coronavirus SARS-CoV-2, which is responsible for ...

2020-12-09 20:49 1619

HBM Holdings Limited Announces the Offer Price and Allotment Results of the Global Offering

This press release is NOT for release, publication, distribution, directly or indirectly, in or intothe United States (including its territories and possessions, any state ofthe United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. Thi...

2020-12-09 17:29 6219

Antengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology

SHANGHAI and HONG KONG, Dec. 9, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...

2020-12-09 08:00 3527

Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

SYDNEY, Dec. 9, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT029...

2020-12-09 07:49 3401

Zelgen Selects Industry's First Automated, End-to-End Drug Safety System

Rapidly growing biopharma selects ArisGlobal's LifeSphere® MultiVigilance 10, benefits from industry's first cognitive automation and AI-enabled safety system, a game-changer for patient safety MIAMI, Dec. 9, 2020 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that au...

2020-12-09 05:07 1980

Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease

- ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol® as agreed with U.S. Food and Drug Administration (FDA) - Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial - Topline data expected in 2nd half 2021 HEIDELBERG, Germany,...

2020-12-08 21:00 1301

Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem

SEOUL, South Korea, Dec. 8, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) released a report onDecember 8th that CP-COV03, its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activit...

2020-12-08 21:00 1327

Abcam reveals new cell engineering facility in Bay Area

CAMBRIDGE, England, Dec. 8, 2020 /PRNewswire/ -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the opening of a new 16,000 sq ft purpose-fitted facility inFremont, CA, which will serve as a major new site for its s...

2020-12-08 20:31 5758

Peijia Medical Successfully Commenced Animal Study for its Mitral Valve Edge-to-Edge Repair Product

SUZHOU, China, Dec. 8, 2020 /PRNewswire/ -- Peijia Medical (HK Stock Code: 09996) successfully commenced the animal experiment for its mitral valve edge-to-edge repair product, advancing the development to the next stage. The commencement of this experiment reflects Peijia Medical's long term com...

2020-12-08 20:00 3148

Nuance Pharma Closes Series D Financing

SHANGHAI, Dec. 8, 2020 /PRNewswire/ -- Nuance Pharma, a biopharmaceutical company engaged in creating value throughChina's specialty pharmaceutical markets with an established focus on iron deficiency, pain management and respiratory, today announced that it has successfully closed its Series D ...

2020-12-08 17:34 3145

Nuance Pharma Closes Series D Financing

SHANGHAI, Dec. 8, 2020 /PRNewswire/ -- Nuance Pharma, a biopharmaceutical company engaged in creating value throughChina's specialty pharmaceutical markets with an established focus on iron deficiency, pain management and respiratory, today announced that it has successfully closed its Series D ...

2020-12-08 16:00 4538

Novotech Health Holdings Announces Appointment of Anand Tharmaratnam as Chairman

SHANGHAI and SYDNEY, Dec. 8, 2020 /PRNewswire/ -- Novotech Health Holdings ("Novotech Holdings"), the largest biotech specialist contract research organization (CRO) inAsia, today announced the appointment of Anand Tharmaratnam as Chairman of the Board commencing1 April 2021. Dr Tharmaratnam br...

2020-12-08 13:00 1360
1 ... 265266267268269270271 ... 306

Week's Top Stories